cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.23552256
title: LncRNA KCNQ1OT1 promotes oxaliplatin resistance of ovarian cancer cells through upregulating Bmi1 by sponging miR-128-3p

description: The long non-coding RNA (lncRNA) KCNQ1OT1 exerts oncogenic functions in human cancers, including ovarian cancer (OC). However, the potential role and detailed mechanism of KCNQ1OT1 in modulating chemoresistance in OC remain unclear. Herein, it showed that KCNQ1OT1 expression was upregulated in OC tissues and tissues from oxaliplatin (OHP)-resistant OC patients. KCNQ1OT1 exhibited oncogenic functions in OVCAR3 and A2780 OC cell lines with increased sensitivity of drug-resistant OC cells against OHP. miR-128-3p was identified as a target of KCNQ1OT1 which negatively regulated the expression levels of the former. Overexpression of miR-128-3p reversed the oncogenic effects of KCNQ1OT1 in OC cells and OHP sensitivity. miR-128-3p main target B lymphoma Mo-MLV insertion region 1 homolog (Bmi1) and negatively regulated its expression, while later positively regulated by KCNQ1OT1. The mouse xenograft tumor experiments in vitro and in vivo have demonstrated that KCNQ1OT1 promoted OC progression and oxaliplatin resistance by upregulating Bmi1 by involving miR-128-3p. Taken together, KCNQ1OT1 acts as a molecular target to bind miR-128-3p and regulates the expression levels of Bim1 in cancer cells that consequently promote tumor progression and OHP resistance in OC. The KCNQ1OT1-miR-128-3p-Bmi1 pathway may represent novel targets for OC treatment.
DOI: 10.6084/m9.figshare.23552256.v1
title: LncRNA KCNQ1OT1 promotes oxaliplatin resistance of ovarian cancer cells through upregulating Bmi1 by sponging miR-128-3p

description: The long non-coding RNA (lncRNA) KCNQ1OT1 exerts oncogenic functions in human cancers, including ovarian cancer (OC). However, the potential role and detailed mechanism of KCNQ1OT1 in modulating chemoresistance in OC remain unclear. Herein, it showed that KCNQ1OT1 expression was upregulated in OC tissues and tissues from oxaliplatin (OHP)-resistant OC patients. KCNQ1OT1 exhibited oncogenic functions in OVCAR3 and A2780 OC cell lines with increased sensitivity of drug-resistant OC cells against OHP. miR-128-3p was identified as a target of KCNQ1OT1 which negatively regulated the expression levels of the former. Overexpression of miR-128-3p reversed the oncogenic effects of KCNQ1OT1 in OC cells and OHP sensitivity. miR-128-3p main target B lymphoma Mo-MLV insertion region 1 homolog (Bmi1) and negatively regulated its expression, while later positively regulated by KCNQ1OT1. The mouse xenograft tumor experiments in vitro and in vivo have demonstrated that KCNQ1OT1 promoted OC progression and oxaliplatin resistance by upregulating Bmi1 by involving miR-128-3p. Taken together, KCNQ1OT1 acts as a molecular target to bind miR-128-3p and regulates the expression levels of Bim1 in cancer cells that consequently promote tumor progression and OHP resistance in OC. The KCNQ1OT1-miR-128-3p-Bmi1 pathway may represent novel targets for OC treatment.
DOI: 10.25502/57g6-br27/d
title: Phenotypic data generated from Extra-Early maturing QPM inbred lines and hybrids evaluation under Low soil nitrogen and Striga-infested, and Optimal environments 

description: Phenotypic data generated from Extra-Early maturing QPM inbred lines and hybrids evaluation under Low soil nitrogen and Striga-infested, and Optimal environments Optimal and stress (low soil nitrogen and striga-infested) datasets_Mokwa low-N_2019 & 2020, Abuja and Mokwa_Striga-infested_2020, Abuja_2020 and Mokwa_2019 & 2020_Optimal conditions
DOI: 10.6084/m9.figshare.23544813
title: Supplementary Material for: Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia

description: <b><i>Introduction:</i></b> PRESENCE was a phase 2 clinical trial assessing the efficacy of mevidalen, a D1 receptor positive allosteric modulator, for symptomatic treatment of Lewy body dementia (LBD). Mevidalen demonstrated improvements in motor and non-motor features of LBD, global functioning, and actigraphy-measured activity and daytime sleep. Adverse events (AEs) of fall were numerically increased in mevidalen-treated participants. <b><i>Methods:</i></b> A subset of PRESENCE participants wore a wrist actigraphy device for 2-week periods pre-, during, and posttreatment. Actigraphy sleep and activity measures were derived per period and analyzed to assess for their association with participants’ reports of an AE of fall. Prespecified baseline and treatment-emergent clinical characteristics were also included in the retrospective analysis of falls. Independent-samples <i>t</i> test and χ<sup>2</sup> test were performed to compare the means and proportions between individuals with/without falls. <b><i>Results:</i></b> A trend toward more falls was observed with mevidalen treatment (31/258 mevidalen-treated vs. 4/86 in placebo-treated participants: <i>p</i> = 0.12). Higher body mass index (BMI) (<i>p</i> &lt; 0.05), more severe disease measured by baseline Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part II (<i>p</i> &lt; 0.05), and a trend toward improved Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog<sub>13</sub>) (<i>p</i> = 0.06) were associated with individuals with falls. No statistically significant associations with falls and treatment-emergent changes were observed. <b><i>Conclusion:</i></b> The association of falls with worse baseline disease severity and higher BMI and overall trend toward improvements on cognitive and motor scales suggest that falls in PRESENCE may be related to increased activity in mevidalen-treated participants at greater risk for falling. Future studies to confirm this hypothesis using fall diaries and digital assessments are necessary.
DOI: 10.6084/m9.figshare.23545164
title: Supplementary Material for: Recurrent Hyponatremia in the Setting of Autoimmune Disease with Sicca Syndrome: A Case Report

description: Sjogren’s syndrome is an autoimmune disease associated with xerostomia and xerophthalmia. The association of Sjogren’s with hyponatremia has rarely been reported and has been attributed to syndrome of inappropriate antidiuretic hormone secretion. Here, we report a case of polydipsia secondary to xerostomia as a cause of chronic hyponatremia in the setting of Sjogren’s syndrome. Analysis of the patient’s medical record, including medication reconciliation and dietary habits, revealed several underlying causes of her recurrent hyponatremia. A thorough review of the patient’s clinical history and good bedside examination may reduce prolonged hospitalizations and improve the quality of life of a hyponatremic population of patients who are predominantly elderly.
DOI: 10.6084/m9.figshare.19687665
title: Final Data Set Used for Analyses

description: This is the final data set used for all analyses in the manuscript "The Role of Trait Mindfulness in the Association between Loneliness and Psychological Distress". <br> Information describing all variables used in analyses can be found in the document "Information on Included Files".
DOI: 10.6084/m9.figshare.19687665.v1
title: Final Data Set Used for Analyses

description: This is the final data set used for all analyses in the manuscript "The Role of Trait Mindfulness in the Association between Loneliness and Psychological Distress". <br> Information describing all variables used in analyses can be found in the document "Information on Included Files".
DOI: 10.57745/tt6ktn
title: Phenotypes_data.csv

description: :unav
DOI: 10.57745/ttjk7z
title: Genotypes_data.csv

description: :unav
DOI: 10.57745/vj4wco
title: Phenotypes_metadata.csv

description: Explanation of data contained in file Phenotypes_data
DOI: 10.57745/xay0ad
title: Phenotypes_data.tab

description: Data set of dendrometric data of Pinus nigra salzmannii
DOI: 10.57745/zijhq2
title: Genotypes_metadata.csv

description: Explanation of data contained in file Genotypes_data
DOI: 10.57745/fltmjo
title: Genotypes_data.tab

description: Data set of genotypes of Pinus nigra salzmannii
DOI: 10.57745/jrbeen
title: Meta-data for the table Genotypes_data.tab

description: Readme for the table Genotypes_data.csv
DOI: 10.57745/tt0ubx
title: Meta-data for the table Phenotypes_metadata.tab

description: Readme for the table Phenotypes_metadata
DOI: 10.6084/m9.figshare.19687650
title: Original Unedited Data Set

description: This is the original unedited data set for the manuscript "The Role of Trait Mindfulness in the Association between Loneliness and Psychological Distress". <br> <strong>The survey includes:</strong> Demographics The University of California Los Angeles Loneliness Scale–Version 3 (UCLA-LS; Russell, 1996) The Five-Facet Mindfulness Questionnaire–Short Form (FFMQ-SF; Bohlmeijer et al., 2011) The 21-item Depression, Anxiety, and Stress Scale (DASS-21; Lovibond & Lovibond, 1995) Questions regarding mindfulness and meditation practice Questions regarding relationships and home location and household composition Questions regarding the impact of COVID-19 measures on employment. <em><strong>References</strong></em> Bohlmeijer, E., ten Klooster, P. M., Fledderus, M., Veehof, M., & Baer, R. (2011). Psychometric properties of the Five Facet Mindfulness Questionnaire in depressed adults and development of a short form. Assessment, 18(3), 308-320. https://doi.org/10.1177/1073191111408231 Lovibond, S. H., & Lovibond, P. F. (1995). <em>Manual for the Depression Anxiety Stress Scales</em> (2nd ed.). Psychology Foundation. Russell, D. W. (1996). UCLA Loneliness Scale (Version 3): Reliability, validity, and factor structure. Journal of Personality Assessment, 66(1), 20-40. https://doi.org/10.1207/s15327752jpa6601_2
DOI: 10.6084/m9.figshare.23544825
title: Supplementary Material for: The Impact of Pathogen Reduction on Total IgG and IgG Subclass Profiles of Convalescent Plasma

description: <b><i>Introduction:</i></b> In case of newly emerging pathogens, convalescent plasma (CP) is often the only early available treatment option. It has been shown that different IgG subclasses contribute differently to CP neutralizing activity. As CP donors often have a risk profile like first-time donors, especially with respect to window-period viral transmission, pathogen reduction (PR) could mitigate that risk. The aim of our study, especially in the light of potential future pandemics, was to evaluate the impact of commercially available PR technologies on total IgG and IgG subclasses quantity and distribution in CP using COVID-19 CP (CCP) as surrogate for CP in a side-by-side comparison approach. <b><i>Methods:</i></b> 36 apheresis CCP donations were allocated to three study groups and a side-by-side assessment of the potential impact of amotosalen (AS)/UVA treatment compared to a riboflavin (RB)/UVB treatment, AS against methylene blue (MB) treatment, and RB against MB treatment on the quantity of IgG and IgG subclasses with a nephelometric analyzer was performed. <b><i>Results:</i></b> IgG subclass distributions were not significantly changed post PR treatment with all three technologies. There was also no significant difference in the median loss of concentration for IgG1 and IgG2 between the three technologies. We recognized a non-significant trend of a higher IgG4 median loss post RB treatment compared to post AS and MB treatment, respectively. <b><i>Conclusion:</i></b> Although the three commercially available PR systems do not significantly alter the distribution of IgG subclasses, we detected a non-significant trend of higher IgG4 loss after RB treatment. The potential impact of that finding needs further investigation.
DOI: 10.6084/m9.figshare.23544825.v1
title: Supplementary Material for: The Impact of Pathogen Reduction on Total IgG and IgG Subclass Profiles of Convalescent Plasma

description: <b><i>Introduction:</i></b> In case of newly emerging pathogens, convalescent plasma (CP) is often the only early available treatment option. It has been shown that different IgG subclasses contribute differently to CP neutralizing activity. As CP donors often have a risk profile like first-time donors, especially with respect to window-period viral transmission, pathogen reduction (PR) could mitigate that risk. The aim of our study, especially in the light of potential future pandemics, was to evaluate the impact of commercially available PR technologies on total IgG and IgG subclasses quantity and distribution in CP using COVID-19 CP (CCP) as surrogate for CP in a side-by-side comparison approach. <b><i>Methods:</i></b> 36 apheresis CCP donations were allocated to three study groups and a side-by-side assessment of the potential impact of amotosalen (AS)/UVA treatment compared to a riboflavin (RB)/UVB treatment, AS against methylene blue (MB) treatment, and RB against MB treatment on the quantity of IgG and IgG subclasses with a nephelometric analyzer was performed. <b><i>Results:</i></b> IgG subclass distributions were not significantly changed post PR treatment with all three technologies. There was also no significant difference in the median loss of concentration for IgG1 and IgG2 between the three technologies. We recognized a non-significant trend of a higher IgG4 median loss post RB treatment compared to post AS and MB treatment, respectively. <b><i>Conclusion:</i></b> Although the three commercially available PR systems do not significantly alter the distribution of IgG subclasses, we detected a non-significant trend of higher IgG4 loss after RB treatment. The potential impact of that finding needs further investigation.
DOI: 10.5281/zenodo.8063682
title: Rapid shoaling of Aragonite Saturation Horizon (ASH) in the Indian Ocean: Influence of accumulation of anthropogenic CO2 and atmospheric pollutants

description: This data set contains the various cruise data of Aragonite saturation depth in the Northern Indian Ocean. The shallowest aragonite saturation horizon (ASH) was observed in the Bay of Bengal (BoB; 219±10 m) within the tropical Indian Ocean. The ASH shoaled at the rate of 6.3±5 and 4.4±3 m y<sup>-1</sup> in the past two and half decades in the BoB and Arabian Sea respectively. As a result, an increase in total alkalinity (TA) was observed at the rate of 0.5±0.3 and 0.25±0.2 mmol kg<sup>-1</sup> y<sup>-1</sup> at the depth of ASH in the BoB, and Arabian Sea respectively. The rapid shoaling of ASH in the BoB than the Arabian Sea may result from the higher accumulation of anthropogenic CO<sub>2</sub> due to the freshening of the upper ocean associated with an increase in river discharge/ precipitation and deposition of atmospheric pollutants leading to corrosion of the aragonite skeletal material. Under a business-as-usual scenario, aragonite-secreting organisms may not survive by the middle of this century in the BoB.
DOI: 10.5281/zenodo.8063681
title: Rapid shoaling of Aragonite Saturation Horizon (ASH) in the Indian Ocean: Influence of accumulation of anthropogenic CO2 and atmospheric pollutants

description: This data set contains the various cruise data of Aragonite saturation depth in the Northern Indian Ocean. The shallowest aragonite saturation horizon (ASH) was observed in the Bay of Bengal (BoB; 219±10 m) within the tropical Indian Ocean. The ASH shoaled at the rate of 6.3±5 and 4.4±3 m y<sup>-1</sup> in the past two and half decades in the BoB and Arabian Sea respectively. As a result, an increase in total alkalinity (TA) was observed at the rate of 0.5±0.3 and 0.25±0.2 mmol kg<sup>-1</sup> y<sup>-1</sup> at the depth of ASH in the BoB, and Arabian Sea respectively. The rapid shoaling of ASH in the BoB than the Arabian Sea may result from the higher accumulation of anthropogenic CO<sub>2</sub> due to the freshening of the upper ocean associated with an increase in river discharge/ precipitation and deposition of atmospheric pollutants leading to corrosion of the aragonite skeletal material. Under a business-as-usual scenario, aragonite-secreting organisms may not survive by the middle of this century in the BoB.
DOI: 10.5281/zenodo.6406569
title: forTEXT/EvENT_Dataset: v.1.0

description: Manual Event Annotations
DOI: 10.6084/m9.figshare.22924001.v1
title: Supplementary Material for: Documented adverse drug reactions and discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease

description: Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are frequently discontinued in patients with chronic kidney disease (CKD). Documented adverse drug reactions (ADRs) in medical records may provide insight into the reasons for treatment discontinuation. Methods: In this retrospective cohort of U.S. veterans from 2005 to 2019, we identified individuals with CKD and a current prescription for an ACEi or ARB (current user group) or a discontinued prescription within the preceding 5 years (discontinued group). Documented ADRs in structured datasets associated with an ACEi or ARB were categorized into 17 pre-specified groups. Logistic regression assessed associations of documented ADRs with treatment discontinuation. Results: There were 882,441 (73.0%) individuals in the current user group and 326,794 (27.0%) in the discontinued group. There were 26,434 documented ADRs, with at least one documented ADR in 7,520 (0.9%) current users and 9,569 (2.9%) of the discontinued group. ADR presence was associated with treatment discontinuation, aOR 4.16 (95% CI 4.03, 4.29). The most common documented ADRs were cough (37.3%), angioedema (14.2%), and allergic reaction (10.4%). ADRs related to angioedema (aOR 3.81, 95% CI 3.47, 4.17), hyperkalemia (aOR 2.03, 95% CI 1.84, 2.24), peripheral edema (aOR 1.53, 95% CI 1.33, 1.77), or acute kidney injury (aOR 1.32, 95% CI 1.15, 1.51) were associated with treatment discontinuation. Conclusions: ADRs leading to drug discontinuation were infrequently documented. ADR types were differentially associated with treatment discontinuation. An understanding of which ADRs lead to treatment discontinuation provides an opportunity to address them at a healthcare system level.
DOI: 10.6084/m9.figshare.22811483
title: Supplementary Material for: Pediatric Glioma Models Provide Insights into Tumor Development and Future Therapeutic Strategies

description: In depth study of pediatric gliomas has been hampered due to difficulties in accessing patient tissue and a lack of clinically-representative tumor models. Over the last decade, however, profiling of carefully curated cohorts of pediatric tumors has identified genetic drivers that molecularly segregate pediatric gliomas from adult gliomas. This information has inspired the development of a new set of powerful in vitro and in vivo tumor models that can aid in identifying pediatric-specific oncogenic mechanisms and tumor-microenvironment interactions. Single-cell analyses of both human tumors and these newly developed models has revealed that pediatric gliomas arise from spatiotemporally discrete neural progenitor populations in which developmental programs have become dysregulated. pHGGs also harbor distinct sets of co-segregating genetic and epigenetic alterations, often accompanied by unique features within the tumor microenvironment. The development of these novel tools and data resources has led to insights into the biology and heterogeneity of these tumors, including identification of distinctive sets of driver mutations, developmentally restricted cells of origin, recognizable patterns of tumor progression, characteristic immune environments, and tumor hijacking of normal microenvironmental and neural programs. As concerted efforts have broadened our understanding of these tumors, new therapeutic vulnerabilities have been identified, and for the first time promising new strategies are being evaluated in the preclinical and clinical settings. Even so, dedicated and sustained collaborative efforts are necessary to refine our knowledge and bring these new strategies into general clinical use. In this review, we will discuss the range of currently available glioma models, the way in which they have each contributed to recent developments in the field, their benefits and drawbacks for addressing specific research questions, and their future utility in advancing biological understanding and treatment of pediatric glioma.
DOI: 10.6084/m9.figshare.23552319.v1
title: Isotopic and geochemical characteristics of Mid-to-Late-Miocene continental and oceanic arc volcanic and intrusive rocks, central North Island and offshore, New Zealand

description: S3: precision of major and trace element data set
DOI: 10.6084/m9.figshare.23552319
title: Isotopic and geochemical characteristics of Mid-to-Late-Miocene continental and oceanic arc volcanic and intrusive rocks, central North Island and offshore, New Zealand

description: S3: precision of major and trace element data set
DOI: 10.6084/m9.figshare.23552325
title: Isotopic and geochemical characteristics of Mid-to-Late-Miocene continental and oceanic arc volcanic and intrusive rocks, central North Island and offshore, New Zealand

description: S1: sample locations
DOI: 10.6084/m9.figshare.23552325.v1
title: Isotopic and geochemical characteristics of Mid-to-Late-Miocene continental and oceanic arc volcanic and intrusive rocks, central North Island and offshore, New Zealand

description: S1: sample locations
DOI: 10.6084/m9.figshare.23552331
title: Isotopic and geochemical characteristics of Mid-to-Late-Miocene continental and oceanic arc volcanic and intrusive rocks, central North Island and offshore, New Zealand

description: S2: geochemical tables
DOI: 10.6084/m9.figshare.23552331.v1
title: Isotopic and geochemical characteristics of Mid-to-Late-Miocene continental and oceanic arc volcanic and intrusive rocks, central North Island and offshore, New Zealand

description: S2: geochemical tables
DOI: 10.23729/8c42abc7-58e0-4bad-afab-d2ca31411cdb
title: HITEC EB11-nano

description: Nanofocus scans of EB11 sample of HITEC. Collective preview dataset at https://doi.org/10.23729/170132f5-ecba-4dc8-b248-001dc5795db5 Preview dataset found at https://doi.org/10.23729/58539508-f6a5-4a5c-8f05-1ed8093fac20 . To obtain data, please contact fairdata-pas@gtk.fi .
DOI: 10.6084/m9.figshare.23514348.v1
title: Data (Pengam et al)

description: The benefits of regular physical exercise are mainly mediated by the stimulation of oxidative and antioxidant capacities in skeletal muscle, although the cellular and molecular responses are not fully elucidated. The main aim of the present study was to compare the effects of two types of exercise training protocol: a moderate-intensity continuous training (MICT) and a high-intensity interval training (HIIT) on metabolic processes in two muscles with different typologies: <em>soleus</em> and <em>extensor digitorum longus</em> (EDL). Training effects in male Wistar rats were studied from whole organism level (maximal aerobic speed, morphometric and systemic parameters) to muscle level (transcripts, protein contents and enzymatic activities involved in antioxidant defences, aerobic and anaerobic metabolisms). Wistar rats were randomly divided into three groups: untrained (UNTR), <em>n</em> = 7; MICT, <em>n</em> = 8; and HIIT, <em>n</em> = 8. Rats of the MICT and HIIT groups ran five times a week for six weeks at moderate and high intensity, respectively. HIIT improved the endurance performance (increased maximal aerobic speed) and oxidative capacities more than MICT in both muscles, as determined through protein and transcript assays (AMPK–PGC-1α signalling pathway, antioxidant defences, mitochondrial functioning and dynamics). Whatever the training protocol, the genes involved in these processes were largely more significantly upregulated in <em>soleus</em> (slow-twitch fibres) than in EDL (fast-twitch fibres). Solely on the basis of the transcript changes, we conclude that the training protocols tested here lead to specific muscular responses.
DOI: 10.25500/edata.bham.00000962
title: Data to accompany "Tissue washing improves native ambient mass spectrometry detection of membrane proteins directly from tissue"